NEW YORK, Oct. 22, 2013 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Osiris Therapeutics, Inc. ("Osiris" or the "Company") (NasdaqGM: OSIR). Such investors are advised to contact Peretz Bronstein or his Investor Relations coordinator Eitan Kimelman at email@example.com or 212-697-6484.
The investigation concerns whether Osiris and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On October 21, 2013, shares of Osiris fell $2.98 or 17.01% to close at $14.51 after the company said the Food and Drug Administration will treat its wound care product Grafix as a drug. The company said Grafix will remain on the market, but it will file a Biologics License Application to expand the drug's approval. According to the October 20, 2013 regulatory filing the Company will resolve concerns the FDA raised in an untitled letter dated September 26, 2013 and that Osiris and the FDA reached a resolution to these concerns on September 30, 2013.
If you are aware of any facts relating to this investigation, or purchased shares of Osiris, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV